DIY FLU
agency: Cadient Group
brand: Fluvirin
client: Novartis
photo from left: Sally Reed, manager, project management • Geoff McCleary, senior marketing strategist • Marisa McGettigan, account manager • Erik Sonlin, associate creative director • On Laptop: David Miller, digital media producer
Many pharmaceutical companies are terrified of dipping even a toe into the swirling pool of viewer-generated content because regulatory issues make a truly unfiltered dialogue impossible. However, Cadient made pharma history with its groundbreaking YouTube Fluflix contest for Novartis's influenza vaccine Fluvirin and the firm's informational Web site FluSource.com.
Cadient presented the YouTube concept, and Novartis got on board, offering $500 to anyone who could create a compelling video flu story in one of the following categories: Kids and the Flu, Sports and the Flu, and Workplace and the Flu. The result? At press time, approximately 800,000 people had viewed the sample videos produced by Novartis and Cadient, and approximately 12,000 people had viewed the FluFlix channel on YouTube. The contest—which was unbranded—also drummed up impressive hits for Novartis's FluSource.com. The winning videos included a retro black-and-white entry, a cartoon entry, and a video featuring the filmmaker's own children.
"We met the challenges of the client, and we think we were able to provide the users with a forum to exercise some creativity," says Geoff McCleary of Cadient. "I think the prevailing thought in the pharma industry is that it's a great thing to try social media, we just wish we knew how to do it. This proves that there are ways."
With pharma scaling back, where will this lead? Last time we checked, YouTube videos were cheaper than flashy commercials. And Cadient's Sally Reed was "astounded" by the quality. "The three winners were exceptional, but the overall talent that's out there and the quality of the product we received on YouTube was amazing."
PREVIOUS AGENCY ‹‹ HOME ›› NEXT AGENCY
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.